BioCentury | Dec 9, 2013
Company News

ChemoCentryx, GlaxoSmithKline deal

...ChemoCentryx said GlaxoSmithKline returned rights to CCX354 , a CC chemokine receptor 1 (CCR1) antagonist that...
...RA). Last year, GSK exercised an option under a 2006 deal to license rights to CCX354...
...of the compound. ChemoCentryx said it is too soon to discuss future development plans for CCX354...
BioCentury | Dec 4, 2013
Company News

GSK returns remaining ChemoCentryx programs

...III trial next year, pending discussions with FDA. ChemoCentryx said GSK also returned rights to CCX354...
...Phase II testing for rheumatoid arthritis (RA). GSK exercised an option to license rights to CCX354...
...it has identified a "more potent" next-generation series of CCR1 inhibitors. GSK said data for CCX354...
BioCentury | Sep 23, 2013
Company News

ChemoCentryx, GlaxoSmithKline deal

...see BioCentury, Dec. 21, 2009). The companies remain partnered under a 2006 deal to develop CCX354...
BioCentury | Sep 19, 2013
Company News

ChemoCentryx regains vercirnon rights from GSK

...31%, p=0.01) (see BioCentury Extra, June 1, 2009) . The companies remain partnered to develop CCX354...
BioCentury | Aug 23, 2013
Top Story

ChemoCentryx plummets on Phase III miss

...II trial of CCX140 to treat diabetic nephropathy this quarter. GSK is also developing ChemoCentryx's CCX354...
BioCentury | Jun 13, 2013
Strategy

Uprooting CEEDD

...four Phase III trials. In 2011, GSK exercised an option for exclusive, worldwide rights to CCX354...
BioCentury | Nov 1, 2012
Distillery Therapeutics

Indication: Various

...and pharmacokinetics. Future studies could include testing the lead compound in animal models of RA. CCX354...
BioCentury | Jun 25, 2012
Clinical News

CCX354: Additional Phase II data

...double-blind, international Phase II CARAT-2 trial in 160 patients showed that once-daily 200 mg oral CCX354...
...21% vs. 13%, p=0.36) at week 12 vs. placebo. The twice-daily 100 mg dose of CCX354...
...of the Rheumatic Diseases. Last November, ChemoCentryx reported that the once-daily 200 mg dose of CCX354...
BioCentury | Feb 13, 2012
Finance

Calculating ChemoCentryx

...has an option on a third. The pharma is funding the development of Traficet-EN and CCX354...
BioCentury | Jan 9, 2012
Company News

ChemoCentryx, GlaxoSmithKline deal

...GlaxoSmithKline exercised an option for exclusive, worldwide rights to develop and commercialize arthritis compound CCX354 from...
...will receive a $25 million option fee, and is eligible for milestones and double-digit royalties. CCX354...
...not disclosed (see BioCentury, Aug. 28, 2006). Last November, ChemoCentryx said once-daily 200 mg oral CCX354...
Items per page:
1 - 10 of 24